Post hoc analysis of the METIMMOX trial in metastatic MSS colorectal cancer (67 analysed): patients on alternating chemotherapy and nivolumab with TMB ≥9 or BRAF-V600E (n=17) had median PFS 19.8 months, longer than other groups.
Secondary analysisn = 67 patients
Ree et al. Exploratory biomarkers for oxaliplatin-induced nivolumab responsiveness in metastatic microsatellite-stable colorectal cancer